Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Me
about
Value of monitoring Nrf2 activity for the detection of chemical and oxidative stressThe Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment OptionsThe effectiveness of dimethyl fumarate monotherapy in the treatment of relapsing-remitting multiple sclerosis: a systematic review and meta-analysis.Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview.Non-electrophilic modulators of the canonical Keap1/Nrf2 pathwayDimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety.The Latest Innovations in the Drug Pipeline for Multiple Sclerosis.The future of multiple sclerosis treatments.Considerations on long-term immuno-intervention in the treatment of multiple sclerosis: an expert opinion.Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases.Emerging Role of Immunity in Cerebral Small Vessel Disease.
P2860
Q26778360-9DA73BE4-A7E2-47BA-907C-2C7B3735872EQ28601505-81D4816B-1D70-481C-A5A7-5748096403C7Q33621682-A1F49A57-EB01-4656-9481-9CF481E16BBCQ34667496-F7A20DBB-C4B1-4675-98E1-F013DFB7827DQ36277241-D19DD4EA-9944-4991-910F-3AC092A82CB6Q38387687-49E625CE-13A9-4822-B32C-22549695E126Q38678739-75FA39F4-A230-4257-9103-CDE3CD6486DDQ38808485-EE506849-F162-4C76-9BCE-FE319CA1AA31Q38946338-FA7D03C9-0CE9-4B83-BA24-0E1B201A5436Q39100528-BE2AA5D2-F859-4B1B-B771-F71640CCDA53Q39325788-FA4072FA-EC80-41E6-917E-365E8F678772Q49408736-955E273D-3EF4-4445-B879-CCE28C22725B
P2860
Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Me
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Oral BG-12 (dimethyl fumarate) ...... ultiple sclerosis. N Engl J Me
@en
type
label
Oral BG-12 (dimethyl fumarate) ...... ultiple sclerosis. N Engl J Me
@en
prefLabel
Oral BG-12 (dimethyl fumarate) ...... ultiple sclerosis. N Engl J Me
@en
P2093
P2860
P1476
Oral BG-12 (dimethyl fumarate) ...... ultiple sclerosis. N Engl J Me
@en
P2093
Kartik Raghupathi
Katherine T Dawson
Marianne T Sweetser
Nuwan C Kurukulasuriya
P2860
P304
P356
10.1517/14656566.2013.826190
P407
P577
2013-08-24T00:00:00Z